Clinical Trial Update: Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating saracatinib in patients with recurrent or metastatic head and neck cancer; results were posted in 2013. The document summarizes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED | Results posted: 2013-10-18